source
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
- FDA moves to speed trials by reviewing AstraZeneca and Amgen data in real time, seeks public input on pilot programThe U.S. Food and Drug Administration announced a new initiative aimed at making clinical trials faster and more efficient. As a first step, the agency will begin reviewing trial data in real time…